- Coordinator
- Institut National De La Sante Et De La Recherche Medicale, France
- Runs
- 1 June 2023 to 31 May 2027
- Status
- Running
- EU funding
- €6.6m
- Total cost
- €6.6m
- Partners
- 19 organisations in 11 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101080690
What the project is doing
In the project's own words, from its summary on CORDIS.
Muscular dystrophies are severe genetic disorders characterised by muscle wasting, impaired mobility and premature death, which to date remain incurable. Although preclinical and clinical evidence position genetic therapies amongst the key emerging treatments for several genetic conditions, no gene therapy or genome editing strategy has been approved for any muscular dystrophies yet. The lack of robust, human(ised) models enabling precise development of such advanced therapies is a major barrier towards their clinical translation for muscle diseases.
To overcome this limitation, we have assembled the multidisciplinary MAGIC consortium to build novel, high-fidelity, models of human skeletal muscle pathophysiology which will be used to develop new vectors for safe and efficacious neuromuscular gene therapy and genome editing. Specific rare (paediatric) diseases targeted by our consortium are Duchenne muscular dystrophy (DMD), X-linked (XLCNM), autosomal dominant (ADCNM) and autosomal recessive (ARCNM) centronuclear myopathies (CNMs), LMNA- and COL6-related congenital muscular dystrophies (CMDs).
Microfabrication, microfluidics and human stem cell differentiation technologies will be used to generate disease-specific human myofiber- and muscle-on-chip devices qualified for commercialisation, capable of screening toxicity and cell-specificity of new adeno-associated viral vector (AAV) capsid variants, and unique muscle-specific lentiviruses. Selected vectors will be equipped with novel lineage-specific regulatory elements to further restrict transgene expression to myofibres, muscle stem cells or interstitial fibroblasts, reducing also potential immunogenicity.
The same vectors will be loaded with therapeutic genes or with new mutation-independent (for DMD and XLCNM) or mutation-specific (for LMNA- and COL6-CMD) gene editing tools, which will then be validated in dystrophic rodents. Finally, GMP-compatible batches of the top performing vectors will undergo advanced preclinical testing in large animals, preparing them for future clinical translation.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Coordinator |
| Siegfried Dinamiqs AG | Schlieren | Switzerland | Associatedpartner |
| Dinabios Deutschland GmbH | Hamburg | Germany | Associatedpartner |
| Medizinische Hochschule Hannover | Hannover | Germany | Participant |
| Vivebiotech SL | San Sebastian | Spain | Participant |
| Universite Paris Xii Val De Marne | Creteil | France | Participant |
| National University of Ireland Maynooth | Maynooth | Ireland | Participant |
| Parent Project Aps | Roma | Italy | Participant |
| Reithera SRL | Roma | Italy | Participant |
| Biond Solutions BV | Delft | Netherlands | Participant |
| Optics11 Life B.V. | Amsterdam | Netherlands | Participant |
| Stichting Duchenne Data Foundation | Soest | Netherlands | Participant |
| Fundacao Gimm - Gulbenkian Institute for Molecular Medicine | Lisboa | Portugal | Participant |
| Regenmed Solutions AB | Stockholm | Sweden | Participant |
| King's College London | London | United Kingdom | Associatedpartner |
| Muscular Dystrophy Group of Great Britain and Northern Ireland | London | United Kingdom | Associatedpartner |
| The Francis Crick Institute Limited | London | United Kingdom | Associatedpartner |
| University College London | London | United Kingdom | Associatedpartner |
| Children's Hospital Medical Center | Cincinnati | United States | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI